Pooling four studies with confirmed first-trimester exposure, researchers found an odds ratio of 0.99 for major malformations, though they flag confounding and comparator limits.
Recap by typeshit. Full story at BIOENGINEER.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Polskie Radio covers the approval timeline for Zepbound, Eli Lilly's tirzepatide shot for weight loss. Details are thin, so tap through for the full story.
Philstar Life reports on FDA worries about unapproved weight loss drugs, including retatrutide, which is still in trials. Few details given, so check the source.
Loading…